Hydrogen Sulfide Ameliorates Cognitive Dysfunction in Formaldehyde-Exposed Rats: Involvement in the Upregulation of Brain-Derived Neurotrophic Factor

2019 ◽  
Vol 79 (2) ◽  
pp. 119-130 ◽  
Author(s):  
Xiang Li ◽  
Yuan-Yuan Zhuang ◽  
Lei Wu ◽  
Ming Xie ◽  
Hong-Feng Gu ◽  
...  
Keyword(s):  
Hydrogen Sulfide ◽  
Cognitive Dysfunction ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor

Forced running exercise mitigates radiation-induced cognitive deficits via regulated DNA hydroxymethylation

Epigenomics ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 385-396 ◽  
Author(s):  
Junjun Zhang ◽  
Junyan Li ◽  
Yiwen Zhu ◽  
Zhigang Miao ◽  
Ye Tian
Keyword(s):  
Cognitive Dysfunction ◽  
Neurotrophic Factor ◽  
Epigenetic Modification ◽  
Brain Derived Neurotrophic Factor ◽  
Hippocampal Neurogenesis ◽  
Mice Model ◽  
Whole Brain Irradiation ◽  
Running Exercise ◽  
Radiation Induced ◽  
Forced Running

Aim: Roles of forced running exercise (FE) in remediation of neurogenesis inhibition and radiation-induced cognitive dysfunction were investigated in a whole-brain irradiation mice model via the regulation of DNA 5-hydroxymethylation modification (5 hmC) and its catalytic enzymes ten–eleven translocation (Tet) proteins. Materials & methods: Hippocampal neurogenesis and cognitive function, DNA 5 hmC level and Tet expression were determined in mice. Results: The expression of DNA 5 hmC and Tet2, brain-derived neurotrophic factor significantly decreased in hippocampus postradiation. FE mitigated radiation-induced neurogenesis deficits and cognitive dysfunction. Furthermore, FE increased 5 hmC and brain-derived neurotrophic factor expression. SC1, a Tet inhibitor, reversed partly such changes. Conclusion: Tet-mediated 5 hmC modification represents a kind of diagnostic biomarkers of radiation-induced cognitive dysfunction. Targeting Tet-related epigenetic modification may be a novel therapeutic strategy for radiation-induced brain injury.

scholarly journals COGNITIVE DYSFUNCTION (CD) AND SERUM LEVELS OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IN PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS)

2019 ◽  
Author(s):  
RENATA FERREIRA ROSA ◽  
MICHELLE REMIÃO UGOLINI-LOPES ◽  
ANA PAULA ROSSI GANDARA ◽  
KENIA REPISO CAMPANHOLO ◽  
LIVIA DUTRA ◽  
...  
Keyword(s):  
Cognitive Dysfunction ◽  
Antiphospholipid Syndrome ◽  
Neurotrophic Factor ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Primary Antiphospholipid Syndrome

Reduced brain-derived neurotrophic factor is associated with cognitive dysfunction in patients with chronic heart failure

2017 ◽  
Vol 17 (5) ◽  
pp. 852-854 ◽  
Author(s):  
Hideaki Suzuki ◽  
Yasuharu Matsumoto ◽  
Hideki Ota ◽  
Koichiro Sugimura ◽  
Jun Takahashi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cognitive Dysfunction ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor

Cognitive dysfunction, brain-derived neurotrophic factor and IL-6 levels in cancer patients with depression

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8632-8632
Author(s):  
C. F. Jehn ◽  
B. Becker ◽  
S. Pfeiffer ◽  
M. Krebs ◽  
K. Possinger ◽  
...  
Keyword(s):  
Cognitive Function ◽  
Cancer Patients ◽  
Cognitive Dysfunction ◽  
Neurotrophic Factor ◽  
Metastatic Cancer ◽  
Pearson Correlation ◽  
Verbal Learning ◽  
Plasma Concentrations ◽  
Brain Derived Neurotrophic Factor ◽  
Longterm Memory

8632 Background: Increased proinflammatory cytokines (IL-6) and decreased brain-derived neurotrophic factor (BDNF) levels have been implicated in the pathophysiology of depression. Depression has been shown to be associated with cognitive dysfunction. The objective of this study was to assess the correlations between cognitive dysfunction, IL-6 and BDNF in cancer patients (pts) with depression. Methods: Depression was assessed in 55 patients with metastatic cancer by the Hospital Anxiety and Depression Scale (HADS) and diagnosis was established according to DSM-IV criteria. Cognitive function was assessed by the Auditory Verbal Learning Test (AVLT). Plasma concentrations of Interleukin-6 and BDNF were measured at 8 AM the same day. In the statistical analysis the Mann-Whitney test and the Pearson correlation were applied. Results: Pts characteristics (n=55): median age 60 y (25–85); 76.9% Females, 23.1% males. 52% of pts had depression. There were no significant differences in mean age or Karnofsky-index between pts with and without depression. Depression was associated with a significant higher median IL-6 level (14.8 vs. 3.7 pg/ml; p<0,001). For Cognitive function only the longterm memory was significantly reduced in depression (p=0.01). However, there was no difference in BDNF levels between both groups (p=0.164). There were correlations between HADS-D score and IL6 (r=4.11; p=0.002), IL-6 and BDNF (r= −0.42; p=0.001), BDNF and longterm memory (r=0.48; p=0.02). No correlations were found for level of depression (HADS-D score) and BDNF levels (r= −0.20; P=0.14). Conclusions: Depression and increased plasma IL-6 concentrations are strongly associated in pts with cancer. There seems to be no association between BDNF and depression in cancer pts. However there is a positive correlation between the cognitive function, at least for longterm memory, with BDNF. No significant financial relationships to disclose.

Cognitive dysfunction and serum levels of brain-derived neurotrophic factor (BDNF) in primary anti-phospholipid syndrome (PAPS)

Rheumatology ◽  
2020 ◽  
Vol 60 (1) ◽  
pp. 179-187
Author(s):  
Renata F Rosa ◽  
Michelle Remião Ugolini-Lopes ◽  
Ana Paula Rossi Gandara ◽  
Margarete B G Vendramini ◽  
Kenia Repiso Campanholo ◽  
...  
Keyword(s):  
Cognitive Dysfunction ◽  
Neural Plasticity ◽  
Neurotrophic Factor ◽  
Univariate Analysis ◽  
Positive Association ◽  
Brain Derived Neurotrophic Factor ◽  
Screening Tests ◽  
Cross Sectional ◽  
Serum Bdnf ◽  
Anti Phospholipid Syndrome

Abstract Objectives Cognitive dysfunction (CD) is a poorly understood non-stroke central neurological manifestation in anti-phospholipid syndrome (APS). Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays an important role in neural plasticity and could potentially be a biomarker of CD in primary APS (PAPS). The aim of the study is to assess CD in PAPS patients and to evaluate its association with clinical data, anti-phospholipid antibodies and serum BDNF levels. Methods This cross-sectional study compared 44 PAPS patients and 20 healthy controls matched for age, gender and education. PAPS patients and controls underwent a standardized cognitive examination. The demographic, clinical and laboratory characteristics of patients were recorded. Serum BDNF was measured by Enzyme Linked Immunosorbent. Results Fourteen (31.8%) of the 44 patients with PAPS had CD compared with only one (5%) healthy control (P =0.019). PAPS patients presented lower serum BDNF levels when compared with controls (P =0.007). Lower levels of BDNF were associated with CD in PAPS patients (P =0.032). In the univariate analysis, a positive association was found between CD and livedo reticularis, deep vein thrombosis, stroke, seizure, smoking as well as a negative association with Mini Mental State Examination and serum BDNF. According to multivariate analysis, the only independent predictor of CD in PAPS was stroke (OR 137.06; 95% CI: 4.73, 3974.32; P =0.004). Conclusions CD is commonly reported in PAPS patients; however, its assessment lacks in standards and objective screening tests. The association between CD and low serum BDNF suggests that this neurotrophin can be a promising biomarker for PAPS cognitive impairment.

Sign in / Sign up

Export Citation Format

Share Document